Lite Strategy, Inc. (LITS)
NASDAQ: LITS · Real-Time Price · USD
1.140
-0.030 (-2.56%)
At close: Apr 28, 2026, 4:00 PM EDT
1.136
-0.004 (-0.32%)
After-hours: Apr 28, 2026, 6:53 PM EDT
Lite Strategy Market Cap
Lite Strategy has a market cap or net worth of $41.45 million as of April 28, 2026. Its market cap has increased by 231.62% in one year.
Market Cap
41.45M
Enterprise Value
32.69M
1-Year Change
231.62%
Ranking
Category
Stock Price
$1.14
Market Cap Chart
Since December 18, 2003, Lite Strategy's market cap has decreased from $424.10M to $41.45M, a decrease of -90.23%. That is a compound annual growth rate of -9.87%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 27, 2026 | 42.50M | -12.55% |
| Dec 31, 2025 | 48.60M | 196.34% |
| Dec 31, 2024 | 16.40M | -57.51% |
| Dec 29, 2023 | 38.60M | 18.77% |
| Dec 30, 2022 | 32.50M | -89.20% |
| Dec 31, 2021 | 301.00M | 1.31% |
| Dec 31, 2020 | 297.10M | 62.62% |
| Dec 31, 2019 | 182.70M | -2.72% |
| Dec 31, 2018 | 187.80M | 141.70% |
| Dec 29, 2017 | 77.70M | 46.60% |
| Dec 30, 2016 | 53.00M | -2.93% |
| Dec 31, 2015 | 54.60M | -40.85% |
| Dec 31, 2014 | 92.30M | -46.40% |
| Dec 31, 2013 | 172.20M | 580.63% |
| Dec 31, 2012 | 25.30M | 105.69% |
| Dec 30, 2011 | 12.30M | 73.24% |
| Dec 31, 2010 | 7.10M | -86.19% |
| Dec 31, 2009 | 51.40M | - |
| Dec 31, 2008 | 51.40M | -74.17% |
| Dec 31, 2007 | 199.00M | 2.58% |
| Dec 29, 2006 | 194.00M | -45.49% |
| Dec 30, 2005 | 355.90M | -30.12% |
| Dec 31, 2004 | 509.30M | -23.48% |
| Dec 31, 2003 | 665.60M | 56.94% |
View and export this data all the way back to 2003.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Dogwood Therapeutics | 45.09M |
| Mereo BioPharma Group | 44.17M |
| Lixte Biotechnology Holdings | 42.29M |
| Cue Biopharma | 41.05M |
| Rein Therapeutics | 40.94M |
| Palatin Technologies | 40.76M |
| Plus Therapeutics | 40.01M |
| Atara Biotherapeutics | 39.21M |